256 related articles for article (PubMed ID: 19640206)
21. Motexafin-gadolinium taken up in vitro by at least 90% of glioblastoma cell nuclei.
De Stasio G; Rajesh D; Ford JM; Daniels MJ; Erhardt RJ; Frazer BH; Tyliszczak T; Gilles MK; Conhaim RL; Howard SP; Fowler JF; Estève F; Mehta MP
Clin Cancer Res; 2006 Jan; 12(1):206-13. PubMed ID: 16397044
[TBL] [Abstract][Full Text] [Related]
22. The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics.
Olson JJ; Paleologos NA; Gaspar LE; Robinson PD; Morris RE; Ammirati M; Andrews DW; Asher AL; Burri SH; Cobbs CS; Kondziolka D; Linskey ME; Loeffler JS; McDermott M; Mehta MP; Mikkelsen T; Patchell RA; Ryken TC; Kalkanis SN
J Neurooncol; 2010 Jan; 96(1):115-42. PubMed ID: 19957013
[TBL] [Abstract][Full Text] [Related]
23. 10-gallon molecule stomps tumors.
Adams A
Science; 1998 Feb; 279(5355):1307-8. PubMed ID: 9508706
[No Abstract] [Full Text] [Related]
24. Therapeutic advances in the treatment of brain metastases.
Chang JE; Robins HI; Mehta MP
Clin Adv Hematol Oncol; 2007 Jan; 5(1):54-64. PubMed ID: 17339829
[TBL] [Abstract][Full Text] [Related]
25. [Current strategies in radiation therapy for brain metastases].
Nakasu Y
No Shinkei Geka; 2007 Jan; 35(1):7-16. PubMed ID: 17228763
[No Abstract] [Full Text] [Related]
26. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme.
Chang JE; Khuntia D; Robins HI; Mehta MP
Clin Adv Hematol Oncol; 2007 Nov; 5(11):894-902, 907-15. PubMed ID: 18185489
[TBL] [Abstract][Full Text] [Related]
27. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? (Review).
van Vulpen M; Kal HB; Taphoorn MJ; El-Sharouni SY
Oncol Rep; 2002; 9(4):683-8. PubMed ID: 12066192
[TBL] [Abstract][Full Text] [Related]
28. Novel radiation sensitizers targeting tissue hypoxia.
Rowinsky EK
Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):61-70. PubMed ID: 10550828
[TBL] [Abstract][Full Text] [Related]
29. Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium.
Doolittle ND; Abrey LE; Ferrari N; Hall WA; Laws ER; McLendon RE; Muldoon LL; Peereboom D; Peterson DR; Reynolds CP; Senter P; Neuwelt EA
Clin Cancer Res; 2002 Jun; 8(6):1702-9. PubMed ID: 12060607
[TBL] [Abstract][Full Text] [Related]
30. Noninvasive and nondestructive optical spectroscopic measurement of motexafin gadolinium in mouse tissues: comparison to high-performance liquid chromatography.
Kanick SC; Eiseman JL; Joseph E; Guo J; Parker RS
J Photochem Photobiol B; 2007 Sep; 88(2-3):90-104. PubMed ID: 17604637
[TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetics of motexafin gadolinium in adults with brain metastases or glioblastoma multiforme.
Miles DR; Smith JA; Phan SC; Hutcheson SJ; Renschler MF; Ford JM; Boswell GW
J Clin Pharmacol; 2005 Mar; 45(3):299-312. PubMed ID: 15703365
[TBL] [Abstract][Full Text] [Related]
32. Motexafin gadolinium injection for the treatment of brain metastases in patients with non-small cell lung cancer.
Thomas SR; Khuntia D
Int J Nanomedicine; 2007; 2(1):79-87. PubMed ID: 17722515
[TBL] [Abstract][Full Text] [Related]
33. The emerging role of reactive oxygen species in cancer therapy.
Renschler MF
Eur J Cancer; 2004 Sep; 40(13):1934-40. PubMed ID: 15315800
[TBL] [Abstract][Full Text] [Related]
34. [Concomitant chemoradiotherapy and malignant glial tumors in the adult].
Honnorat J
Cancer Radiother; 1998 Dec; 2(6):672-8. PubMed ID: 9922772
[TBL] [Abstract][Full Text] [Related]
35. Motexafin gadolinium: a possible new radiosensitiser.
Rodrigus P
Expert Opin Investig Drugs; 2003 Jul; 12(7):1205-10. PubMed ID: 12831354
[TBL] [Abstract][Full Text] [Related]
36. MRI measurement of the uptake and retention of motexafin gadolinium in glioblastoma multiforme and uninvolved normal human brain.
Wu GN; Ford JM; Alger JR
J Neurooncol; 2006 Mar; 77(1):95-103. PubMed ID: 16547607
[TBL] [Abstract][Full Text] [Related]
37. Radiation therapy in the management of brain metastases from renal cell carcinoma.
Doh LS; Amato R; Paulino AC; Teh BS
Oncology (Williston Park); 2006 May; 20(6):603-13; discussion 613, 616, 619-20 passsim. PubMed ID: 16773845
[TBL] [Abstract][Full Text] [Related]
38. Novel chemoradiosensitizers for cancer therapy.
Page P; Yang LX
Anticancer Res; 2010 Sep; 30(9):3675-82. PubMed ID: 20944153
[TBL] [Abstract][Full Text] [Related]
39. Brain tumors.
Obbens EA; Shapiro WR
Cancer Chemother Biol Response Modif; 1993; 14():606-27. PubMed ID: 8312122
[No Abstract] [Full Text] [Related]
40. Cranial radiation therapy and damage to hippocampal neurogenesis.
Monje M
Dev Disabil Res Rev; 2008; 14(3):238-42. PubMed ID: 18924155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
